Granite Falls, WA, United States of America

Paul O Sheppard

USPTO Granted Patents = 163 

 

 

Average Co-Inventor Count = 3.2

ph-index = 20

Forward Citations = 1,615(Granted Patents)


Inventors with similar research interests:


Location History:

  • Redmond, WA (US) (1994 - 2009)
  • Fall City, WA (US) (2009)
  • Seattle, WA (US) (2011)
  • Granite Falls, WA (US) (2001 - 2024)

Company Filing History:


Years Active: 1994-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
TIM3 Antibodies
VISTA Antibodies
TIGIT Antibodies
Bispecific Antibodies
Cytokine Protein Family
IL-17A/F
IL-23P19
ZCYTO20
ZCYTO21
ZVEGF3
Hepatitis C Treatment
Cancer Immunotherapy
163 patents (USPTO):Explore Patents

Title: Paul O Sheppard: Pioneering Innovations in Cancer Treatment

Introduction:

In the realm of medical advancements, there are individuals who passionately dedicate their careers to transforming the way we approach diseases. One such innovator is Paul O Sheppard, a prolific inventor hailing from Granite Falls, WA (US). With an impressive portfolio of 156 patents, his expertise lies in developing groundbreaking therapeutic solutions, specifically in the realm of cancer treatment. In this article, we will delve into Mr. Sheppard's latest patents, career highlights, notable collaborations, and the immense impact his work has had on the field.

Latest Patents:

Paul O Sheppard's recent patents highlight his research in the field of immunotherapy and the development of targeted treatments for cancer. His patent titled "Antibodies binding to VISTA at acidic pH" presents antibodies that specifically target the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH. These antibodies exhibit promising potential in cancer treatment by selectively binding to human VISTA at acidic pH, without significant binding to the protein at neutral or physiological pH.

Another noteworthy patent is titled "Antibodies against TIM3 and uses thereof." It introduces antibodies and their antigen-binding counterparts that specifically bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. These antibodies open new avenues for therapeutic applications, especially in the treatment of cancer.

Career Highlights:

Having worked with esteemed companies like Zymogenetics, Inc and Zymogenetics Corporation, Paul O Sheppard has played a pivotal role in advancing the field of biotechnology. His career highlights include the successful development of novel therapies, pioneering research in immunology, and securing patents for innovative medical technologies.

Collaborations:

Throughout his career, Paul O Sheppard has collaborated with prominent experts in the field. Notably, he has worked alongside Kevin M Klucher and Thomas R Bukowski, who have contributed significantly to his research and accomplishments. These collaborations have fostered an environment of knowledge-sharing and innovation, enabling the creation of transformative solutions in cancer treatment.

Conclusion:

Paul O Sheppard's contributions to the field of medical science have propelled advancements in cancer treatment. His groundbreaking patents in immunotherapy, specifically targeting VISTA and TIM3 proteins, highlight his commitment to developing novel therapeutic approaches. Through collaborations with esteemed colleagues, Sheppard has cemented his position as a trailblazer in the biotechnology industry. With numerous patents under his belt and an unwavering passion for making a difference in patients' lives, Paul O Sheppard continues to inspire a new wave of innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…